Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update - PubMed
6 hours ago
- #MODY
- #systematic review
- #precision medicine
- MODY is a rare monogenic diabetes requiring precision medicine based on molecular diagnosis.
- Sulfonylureas are first-line for HNF1A-, HNF4A-, ABCC8-, and KCNJ11-MODY, often improving glycemic control and allowing insulin transition.
- GCK-MODY typically needs no drugs outside pregnancy, but dorzagliatin may offer new precision treatment options.
- Insulin is mainstay for HNF1B- and INS-MODY, though adjunctive therapies may provide benefits.
- Incretin-based therapies and SGLT2 inhibitors remain exploratory, with evidence limited to small studies and case reports.
- Evidence is limited by small, heterogeneous observational studies, restricting the strength and generalizability of recommendations.